Company Analysis Globus Medical
1. Summary
Advantages
- The stock's return over the last year (54.27%) is higher than the sector average (-15.65%).
- The company's current efficiency (ROE=3.07%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (86.73 $) is higher than fair price (11.54 $)
- Dividends (0%) are below the sector average (1.29%).
- Current debt level 8.44% has increased over 5 years from 0.1632%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Globus Medical | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.3% | -13.6% | 2.9% |
| 90 days | 21.8% | -21.4% | 2.4% |
| 1 year | 54.3% | -15.7% | 26.4% |
GMED vs Sector: Globus Medical has outperformed the "Healthcare" sector by 69.93% over the past year.
GMED vs Market: Globus Medical has outperformed the market by 27.87% over the past year.
Stable price: GMED is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GMED with weekly volatility of 1.04% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (86.73 $) is higher than the fair price (11.54 $).
Price is higher than fair: The current price (86.73 $) is 86.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (50.07) is lower than that of the sector as a whole (57.86).
P/E vs Market: The company's P/E (50.07) is higher than that of the market as a whole (47.62).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.54) is lower than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (1.54) is lower than that of the market as a whole (22.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.92) is lower than that of the sector as a whole (4.06).
P/S vs Market: The company's P/S indicator (3.92) is lower than that of the market as a whole (15.2).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.47) is lower than that of the sector as a whole (17.55).
EV/Ebitda vs Market: The company's EV/Ebitda (15.47) is lower than that of the market as a whole (19.68).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 4.09% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (4.09%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-66.62%).
5.4. ROE
ROE vs Sector: The company's ROE (3.07%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (3.07%) is lower than that of the market as a whole (18.07%).
5.5. ROA
ROA vs Sector: The company's ROA (2.42%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (2.42%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (8.48%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (8.48%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.29%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 21.11.2024 | Lemaitre Dan Director |
Purchase | 85 | 1 221 880 | 14 375 |
| 16.10.2024 | Davidar David D Director |
Purchase | 75 | 2 250 000 | 30 000 |
| 16.10.2024 | Davidar David D Director |
Purchase | 75 | 1 500 000 | 20 000 |
| 16.10.2024 | Davidar David D Director |
Purchase | 74.96 | 262 360 | 3 500 |
| 16.10.2024 | Huller Kelly Officer |
Purchase | 74.97 | 562 275 | 7 500 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
